Ifo-Cell N 2000 (Ifosfamide)

Ifosfamide is an alkylating chemotherapy agent used in the management of several solid tumours.

• Testicular cancer: used in combination regimens to achieve tumour reduction and improve survival.
• Ovarian cancer: incorporated into platinum‑based protocols to enhance response rates.
• Soft tissue sarcoma: administered to control disease progression and facilitate surgical resection.
• Non‑small cell lung cancer: employed as part of multi‑drug therapy for advanced stages.
• Bladder cancer: used in neoadjuvant or adjuvant settings to increase disease‑free intervals.

• Ifosfamide is a nitrogen mustard pro‑drug that is bio‑activated in the liver to form phosphoramide mustard. This metabolite alkylates the N7 position of guanine bases in DNA, creating interstrand cross‑links that block DNA replication and transcription. The resulting DNA damage triggers apoptosis in rapidly dividing cancer cells, while secondary metabolites may also interfere with RNA synthesis.

Ifosfamide can cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during and after infusion.
• Alopecia: reversible hair loss occurring weeks after treatment.
• Fatigue: generalized tiredness that may persist between cycles.
• Myelosuppression: decreased white blood cells, red cells and platelets.
• Hemorrhagic cystitis: bladder irritation due to toxic metabolites.
• Electrolyte disturbances: especially low potassium and magnesium.

Serious or Rare Side Effects

• Nephrotoxicity: acute kidney injury requiring monitoring of renal function.
• Neurotoxicity: encephalopathy, seizures or confusion, especially at high doses.
• Severe infection: opportunistic infections secondary to profound immunosuppression.
• Secondary malignancies: risk of therapy‑related leukemias.
• Cardiotoxicity: rare cardiac dysfunction or arrhythmias.
• Hypersensitivity reactions: anaphylaxis or severe skin rash.

When using Ifosfamide, careful monitoring and specific precautions are essential to minimise risks.

• Renal function monitoring: assess baseline creatinine and maintain adequate hydration before and after infusion.
• Hematologic monitoring: perform weekly complete blood counts to detect myelosuppression.
• Neurotoxicity monitoring: observe patients for confusion, seizures or other neurologic changes.
• Pregnancy avoidance: contraindicated in pregnancy due to proven teratogenicity; use effective contraception.
• Drug interaction vigilance: avoid concurrent nephrotoxic agents and adjust doses of interacting medications.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Ifosfamide may interact with several medicines, requiring either avoidance or close monitoring.

Major Interactions (Avoid)

• Aminoglycosides: increase risk of nephrotoxicity.
• Cisplatin: additive renal toxicity and electrolyte disturbances.
• Methylene blue: may inhibit hepatic activation of ifosfamide.

Moderate Interactions (Monitor Closely)

• Warfarin: potential enhancement of anticoagulant effect, monitor INR.
• Erythropoietin: may mask anemia caused by myelosuppression.
• Anticonvulsants (e.g., phenytoin): may alter neurotoxicity risk, adjust dosing as needed.